Assignee
AMMAX BIO INC
US·5 granted patents·4 pending applications·2 citations·filing 2021–2024
Top patents by PatentIndex Score
9 records- 0189US11752096B2Targeted delivery of anti-CSF1R antibodies to joints with tenosynovial giant cell tumorsAMMAX BIO INC·Filed 2022·Granted Sep 12, 2023·1 cites·18 claims
- 0288US11419822B2High concentration formulations of anti-CSF1 and anti-CSF1R antibodiesAMMAX BIO INC·Filed 2021·Granted Aug 23, 2022·1 cites·13 claims
- 0380US2025073170A1High concentration formulations of anti-csf1 and anti-csf1r antibodiesAMMAX BIO INC·Filed 2024·Application pending·0 cites
- 0477US12178915B2High concentration formulations of anti-CSF1 and anti-CSF1R antibodiesAMMAX BIO INC·Filed 2022·Granted Dec 31, 2024·0 cites·10 claims
- 0574US12371501B2Extended local release of anti-CSFR1 antibodiesAMMAX BIO INC·Filed 2022·Granted Jul 29, 2025·0 cites·11 claims
- 0672US2024016730A1Targeted delivery of anti-csf1r antibodiesAMMAX BIO INC·Filed 2023·Application pending·0 cites
- 0771US11427641B2Extended local release of anti-CSFR1 antibodiesAMMAX BIO INC·Filed 2022·Granted Aug 30, 2022·0 cites·5 claims
- 0864US2026085124A1Treatment of tenosynovial giant cell tumorAMMAX BIO INC·Filed 2023·Application pending·0 cites
- 0959US2023152330A1Detection and treatment of idiopathic pulmonary fibrosisAMMAX BIO INC·Filed 2022·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →